Analysis
Oura filed publicly for a US initial public offering on Sept. 3, confirming a Nasdaq listing under the ticker OURA in an offering Bloomberg reported could raise as much as $3 billion at a valuation above $16 billion. Pulse first covered Oura's IPO ambitions in early September when the company was still described as "eyeing" a listing; this filing converts that reporting into an actual registered offering with real, audited financials attached.
The Numbers Behind the Growth Story
Oura's S-1 shows a growth curve that's accelerating in dollar terms even as the percentage rate normalizes off an unusually high prior-year base:
- 9 months ended June 30, 2026 -- $1.21 billion revenue, up 74% from $697.6 million a year earlier
- Full fiscal 2025 -- $907.9 million revenue, up 123% from $406.8 million in fiscal 2024
- Paid membership -- 5.0 million as of June 30, up from 2.5 million a year earlier, roughly doubling the subscription base in twelve months
Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Company and Jefferies are leading the offering -- a five-bank syndicate reserved for the largest, highest-conviction consumer tech listings of the year.
Why the Subscription Number Is the Real Story
A smart ring is, on its own, a one-time hardware sale with a multi-year replacement cycle -- not a business that supports a growth-stock multiple by itself. What Oura is actually asking public investors to price is the subscription layer sitting on top of the hardware: 5 million paying members generating recurring revenue independent of new-ring sales, the same software-like recurring-revenue argument that let companies like Peloton command growth multiples during their own early public years, before Peloton's growth curve reversed. Oura's bet is that its subscription retention holds up better than Peloton's did -- health data tracking has proven stickier than fitness-class habits for most cohorts studied so far, but Oura's own S-1 is the first document that will let public investors actually test that retention claim against real cohort data rather than narrative.
The Competitive Field Oura Still Leads
Oura remains the category's dominant player by both revenue scale and valuation ambition, but it's not unchallenged: Ultrahuman raised $70 million from Qualcomm Ventures this same week at a $365 million valuation, explicitly positioning its ring as a computing platform rather than just a health tracker. Ultrahuman's 12% subscription attach rate lags well behind what Oura's 5-million-member base implies, underscoring how much of Oura's valuation case rests on a recurring-revenue moat competitors haven't yet replicated at scale. Apple's own health-tracking ambitions inside the Apple Watch remain the more distant, platform-level threat -- a company that doesn't need ring-specific revenue to make wearable health tracking a strategic priority.
What the Filing Doesn't Resolve
Oura's S-1 doesn't yet disclose profitability -- prior reporting on the company's financials described widening losses alongside the revenue surge, a combination public investors will need reconciled before the roadshow prices actual demand. And a $16 billion target valuation on $1.21 billion of nine-month revenue implies a multiple that assumes continued 70%-plus growth for several more years, a bar every high-growth IPO from Peloton to Cerebras has had to clear in its first several quarters as a public company, with mixed results.
What happens next: Oura's roadshow and pricing, expected in the coming weeks, will be the first real market test of whether public investors buy the subscription-hardware thesis at the valuation Oura and its bankers are asking for -- and the first of the eight companies Pulse's earlier coverage identified as 2026 IPO candidates to actually convert from "eyeing" to "filed."
